Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

UNBELIEVABLE: Jasper stock jumps after promising new asthma study results - The Untold Story

Medical Research

Jasper Therapeutics Inc. (NASDAQ:JSPR) on Tuesday released preliminary data from the ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma.

A single subcutaneous 180mg dose of briquilimab demonstrated substantial reductions in sputum eosinophils at both six and twelve weeks, as well as improvements over baseline in FEV1 (key indicator of lung function) in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.